
MICROSATELLITE INSTABILITY OF
COLORECTAL CANCERS IN PATIENTS
FROM THE REPUBLIC OF MACEDONIA
Stefanovska A-M1,*, Jasar D2,*, Zografski G2, Josifovski T3,
Panovski M3, Efremov GD1, Dimovski AJ1
*Corresponding Author: Dr. Aleksandar J. Dimovski, Macedonian Academy of Sciences and Arts, Research Center for Genetic Engineering and Biotechnology, Aven Krste Misirkov 2, POB 428, 1000 Skopje, Republic of Macedonia; Tel: +3892-120253; Fax: +3892-115434; E-mail: aleks@manu.edu.mk page: 11
|
Abstract
Microsatellite instability (MSI) has been found in most hereditary nonpolyposis colorectal cancer HNPCC tumors and in a significantly smaller proportion of sporadic colorectal cancers (CRC). The primary aim of this study was the establishment of an effective assay for MSI detection in our laboratory. The secondary aim was the evaluation of MSI frequency in tumors of CRC patients from the Republic of Macedonia, and the comparison of MSI status with the histopathological features and clinical course of the disease. The fluorescent multiplex polymerase chain reaction (PCR) was found to be the method of choice for routine MSI analyses due to its simplicity, speed and lesser manipulation requirements. Of the five microsatellite markers used in this study, the BAT26 exhibited 100% sensitivity and 100% specificity in the detection of MSI-high phenotype in tumors and could be used as a single marker in MSI analysis. Fourteen of 107 (13.1%) tumors were MSI positive, 11 of which were classified as MSI-H (instability in three or more markers) and three as MSI-L (instability in only one marker). Nodal infiltration was absent in all patients with MSI tumors (p = 0.008).
Statistically significant association was also found with proximal localization (p <0.0001), Dukes' A and B stage of the tumors (p = 0.02) and mucionous histotype (p = 0.05). No association of MSI was found between the patients’ age and gender or with the size and histopathological grade of the tumors.
Key words: Microsatellite instability (MSI), hereditary nonpolyposis colorectal cancer (HNPCC), colorectal cancers (CRC), BAT26
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|